KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31
Karyopharm Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.35−0.04 (-11.30%)
Close on Oct 19, 2026
- Market cap
- $10.01K
- P/E (TTM)
- –
- Dividend yield
- –
Karyopharm Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $114.86M | $112.81M | $112.01M | $120.45M | $98.44M | $76.21M | $30.54M | $0 | – | 78.6% | +1.8% |
| License and Other [Member] | $31.21M | $32.43M | $34.02M | $36.63M | $111.38M | $31.88M | $10.35M | $30.34M | $1.61M | 21.4% | -3.8% |
By region
From the segment and revenue-disaggregation notes of Karyopharm Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.